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Objective: This study compares 3 cohorts of patients with
schizophrenia before, during, and after initiating treatment
with fluphenazine decanoate (FD), haloperidol decanoate
(HD), or long-acting injectable risperidone (LAR).
Methods: Administrative data are analyzed from Califor-
nia Medicaid (Medi-Cal) beneficiaries with schizophrenia
who initiated FD, HD, or LAR treatment. Patients were
required to have been continuously enrolled in Medi-Cal
for 180 days before and 180 days after the start of the new
episode of long-acting antipsychotic therapy. Results:
There were few demographic and clinical differences among
patients initiating FD, HD, and LAR. During the 180 days
before starting long-acting injections, most patients initiat-
ing FD (53.5%), HD (58.5%), and LAR (61.2%) received
oral antipsychotic medications for <80% of the days in this
period (medication possession ratio: <0.80). The mean du-
ration of depot treatment episodes was 58.3 days (SD 5
53.6) for FD, 71.7 days (SD 5 56.4) for HD, and 60.6
days (SD 5 48.8) for LAR (F 5 18.3, df 5 2, 2694,
P < .0001, HD > FD). Few patients who started on FD
(5.4%), HD (9.7%), or LAR (2.6%) continued for at least
180 days. Most patients in each group (FD [77.4%], HD
[78.9%], and LAR [75.5%]) received oral antipsychotic
medications during the 45 days after discontinuing long-
acting injections. Coprescription with antidepressants,
mood stabilizers, and benzodiazepines was common.
Conclusions:Patientstreatedwithlong-actingantipsychotic
injections tend to have complex pharmacological regimens
and recent medication nonadherence. A great majority of
patients initiating long-acting antipsychotic medications
discontinue use within the first few months of treatment.
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Long-acting antipsychotic medication injections are
thought to help improve medication adherence in schizo-
phrenia.
1 Theoretical advantages of long-acting an-
tipsychotic injections over oral medications include
guaranteed delivery of medication, reliable monitoring
of treatment adherence, and an increased opportunity
for the treatment team to intervene as soon as a patient
misses a dose.
2,3 Clinical research
4,5 and expert opinion
6
support use of long-acting injection antipsychotic medi-
cations as maintenance treatment for patients with a his-
tory of medication nonadherence.
Approximately 15% of schizophrenia patients in main-
tenance antipsychotic treatment receive depot prepara-
tions.
7,8 In one recent study, 29.9% of patients with
schizophrenia and a recent history of antipsychotic non-
adherence were currently being prescribed a long-acting
injection antipsychotic medication.
9 In the United States,
psychiatrists tend to select long-acting injection medica-
tions for patients who have persistent psychotic symp-
toms
10,11 and who frequently receive more than one
concurrent antipsychotic medication.
11,12 Use of depot
antipsychotic medications may be increased among
African Americans
11,13 and patients with substance use
problems.
13
Three antipsychotic medications are currently avail-
able in the United States as long-acting injections: flu-
phenazine decanoate (FD) or enanthate, haloperidol
decanoate (HD), and long-acting injectable risperidone
(LAR). These medications differ from one another in
their pharmacokinetic
14–16 and side-effect
17 profiles. Lit-
tle is known about the characteristics and service use pat-
terns of patients who are treated with these medications
in community practice.
In the current report, we use a large administrative da-
tabase to compare and contrast the characteristics of
schizophrenia patients starting FD, HD, and LAR and
assess the continuity of their antipsychotic treatment.
1To whom correspondence should be addressed; tel: 212-543-
5293, e-mail: mo49@columbia.edu.
Schizophrenia Bulletin vol. 33 no. 6 pp. 1379–1387, 2007
doi:10.1093/schbul/sbm033
Advance Access publication on April 29, 2007
 2007 The Authors
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionNon-CommercialLicense(http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
1379We also describe the use of oral antipsychotic and other
psychotropic medications, treatment for selected comor-
bid conditions, and service use before, during, and after
treatment with long-acting antipsychotic medications.
Methods
Statewide service use and pharmacy claims from the
California Medicaid (Medi-Cal) program were analyzed
to assess characteristics of patients with schizophrenia
who were initiating long-acting antipsychotic injections.
The samples were drawn from 4 consecutive years of
Medi-Cal data (2001–2004).
Medi-Calbeneficiaries,18–64yearsofage,withatleast
1inpatientor2outpatientclaimsforschizophrenia(ICD:
295),
18 were selected. Patients were also required to have
been prescribed FD, HD, or LAR and to have been Medi-
Cal enrollees for at least 180 days before and after start-
ing FD, HD, or LAR. For each patient, a 360-day period
including180 days before and 180 days after the first FD,
HD, or LAR injection defined their study period. Be-
cause prescription data were not available during epi-
sodes of inpatient treatment, patients with 90 or more
days of total inpatient treatment or a hospital admission
of greater than 14 days during their 360-day period were
excluded (n = 461).
Analyses were conducted of patients before, during,
and after depot treatment. The before depot treatment
period included the 180 days before the first long-acting
injection. The period during depot treatment started on
the date of the first injection and continued until there
was a gap of more than twice the standard injection treat-
ment interval (ie, 14 days for LAR, 21 days for FD, and
28 days for HD injections). For example, a patient who
received an injection of LAR followed by a second LAR
injection 14 days later but who missed the next 2 injec-
tions was considered to have received a 28-day depot
treatment episode. However, if there were 10 days be-
tweenthefirstandsecondLARinjection,thedepottreat-
ment episode would be considered to be 38 days (14 þ 10
þ 14 days) in duration. A standard injection interval ap-
proach was used rather than relying on the ‘‘days sup-
plied’’ variable that has uncertain validity.
19 Because
the actual injection schedule may not follow these stan-
dard intervals, we also examined the mean number of
injections and period from first to last injection. A 45-
day period after the depot treatment episode was also
studied. Patients were excluded from postdepot treat-
ment analysis if their depot treatment extended to within
45 days of the end of available data.
Patientswerecharacterizedwith respecttoage, gender,
andrace/ethnicity
20,21andbywhethertheyhadbeentrea-
ted for diabetes, obesity, and hyperlipidemia during the
predepot treatment period.
22 Because comorbid sub-
stance use disorder and depression and anxiety disorders
may influence the risk of medication nonadherence,
23,24
the groups were also characterized with respect to
treatment of these disorders. On the basis of the largest
numberofclaims,patientswereconsideredtohaveschizo-
phrenia, schizoaffective disorder, or schizophreniform
disorder. Services use including emergency department
visits, hospital admissions for the treatment of a mental
disorder, and the number of outpatient visits for
mental disorders and general medical disorders was
also examined.
Patients were classified by whether or not they filled
one or more prescription for an antidepressant, anxio-
lytic/hypnotic, and mood stabilizer medication before,
during, and after depot treatment. We also determined
the proportion of patients that received any oral anti-
psychotic medication, a second-generation oral antipsy-
chotic medication, and an oral form of the depot
antipsychotic medication. Other measures of antipsy-
chotic medication treatment included the proportion of
patients with depot treatment of at least 180 days, the
mean duration of continuous depot antipsychotic use,
the mean antipsychotic medication possession ratio
(MPR), and the proportion of patients with an antipsy-
chotic MPR below 0.80. MPR is the proportion of days
supplied of medication during a treatment period. An
MPR of less than 0.80 is commonly accepted as evidence
of medication noncompliance.
3,25
We used chi-square analyses to measurethe strength of
associations between each categorical independent vari-
able and each long-acting antipsychotic medication
group and analysis of variance for continuous indepen-
dent variables. When the omnibus test statistic was sta-
tistically significant (P < .05, 2 tailed), post hoc pairwise
group comparisons were performed with chi squares for
2-level categorical variables and Tukey’s HSD test (P <
.05) for continuous variables. A series of logistic regres-
sion models were fit with each binary service use charac-
teristicasadependentvariable,initialtreatmentwithHD
or FD (LAR reference group) as the independent vari-
able, and duration of treatment episode as a covariate.
Similar analyses were performed with a multiple linear
regression models for continuous variables.
The mean and median duration of long-acting antipsy-
chotic treatment episodes were calculated for the 3 anti-
psychotic groups overall and stratified by age group, sex,
and racial groups (white, other). Confidence intervals
(CIs) were calculated around the means. Accelerated fail-
ure time regressions based on the Weibull distribution
were performed overall and separately by demographic
traits controlling for these characteristics, use of other
mental services, and prescription of other psychotropic
medications. In these analyses, the dependent variable
was time to discontinuation of depot treatment episode.
These regressions yield a survival time ratio (STR). It is
a ratio of the adjusted median time to depot discontinu-
ation between antipsychotic treatment groups with LAR
as the reference group.
M. Olfson et al.
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Prior to Depot Treatment Episode
A majority of patients were started on HD (60.5%), with
fewer patients started on FD (35.2%) or LAR (4.3%).
LAR became available to Medi-Cal recipients in
December 2003. Because of the requirement for at least
180 days of data following the first injection, only
patients who started LAR from December 2003 to
September 2004 were included in the analysis.
Patients who initiated FD were significantly older and
were more likely to be white in race than patients who
initiated HD (table 1). As compared with patients starting
FD, those who started HD or LAR made significantly
fewermentalhealthvisitsandvisitsforthetreatmentgen-
eral medical disorders during the 180 days before their
first injection (table 1).
Over 90% of patients in each group received an oral
antipsychoticmedicationduringthe180daysbeforetheir
first injection (table 2). Treatment with second-generation
oral antipsychotic medications was common in all 3
groups,especiallyamongpatientswhoweresubsequently
started on LAR. Most patients in each group were pre-
scribed a mood stabilizer during the 180 days before their
first injection. Prescriptions for antidepressants and anx-
iolytics/hypnotics were also common during this period
(table 2).
A majorityofpatientsineachgroupreceived2ormore
different oral antipsychotic medications at some point
during the 180 days before their first injection. Patients
were commonly treated with the oral form of the antipsy-
chotic medication that they subsequently received as a
long-acting injection. Although LAR patients were signi-
ficantly more likely than HD or FD patients to have re-
ceived aripiprazole prior to their injection (table 2), this
associationfellbelowthelevelofsignificanceafteradjust-
ing for treatment year (odds ratio [OR] for FD: 1.2, 95%
CI: 0.6–2.4; and OR for HD: 1.3, 95% CI: 0.6–2.5).
Table 1. Background Characteristics of Patients With Schizophrenia During the 180-d Period Before Starting FD, HD, or LAR
Characteristic
FD Patients, %
(N = 948)
HD Patients, %
(N = 1631)
LAR Patients, %
(N = 116)
Statistics
Group
Differences
a Fd f P
Age, mean (SD) 41.2 (10.4) 39.9 (11.0) 39.4 (11.6) 4.8 2, 2692 .008 FD > HD
Number of health care visits
Mental health, (SD) 11.3 (26.6) 7.9 (21.4) 5.1 (7.2) 8.1 2, 2692 .0003 FD > HD, LAR
General medical, (SD) 37.9 (36.1) 31.4 (30.6) 29.4 (31.4) 12.9 2, 2692 .0001 FD > HD, LAR
(%) (%) (%) v
2 df P
Sex 3.8 2 .15
Male 59.5 58.6 50.0
Female 40.5 41.4 50.0
Race 19.7 4 .003
White 51.4 44.7 48.3
African American 20.0 20.5 16.4
Hispanic 4.6 7.0 11.2
Other 24.0 27.8 24.1
Schizophrenia subtype
b 1.8 4 .77
Schizophrenia 73.4 74.6 69.8
Schizoaffective 25.5 24.5 29.3
Schizophreniform 1.1 0.9 0.9
Treatment of selected disorders
c
Obesity 4.6 4.8 1.7 2.3 2 .31
Hyperlipidemia 9.8 8.0 11.2 3.4 2 .18
Diabetes mellitus 8.8 10.4 7.8 2.3 2 .32
Substance use disorder 15.3 15.5 11.2 1.5 2 .46
Depressive disorder 17.4 17.0 24.1 3.8 2 .15
Anxiety disorder 7.3 7.2 7.8 0.1 2 .97
Acute mental health care (%)
Emergency visit 28.6 28.8 28.4 .02 2 .99
Hospital admission 1.0 1.6 0.9 2.1 2 .35
Note: Data from 2001 to 2004 Medi-Cal. FD denotes fluphenazine decanoate, HD denotes haloperidol decanoate, and LAR denotes
long-acting risperidone.
aGroup differences, P < .05.
bBased on the most frequently listed primary diagnosis.
cObesity (ICD-9-CM: 278.0, 783.6, V77.8), hyperlipidemia (272.0–272.4), diabetes mellitus (250), substance use disorder (291, 292, 303–
305), depressive disorders (296.2, 296.3, 300.4, 311), and anxiety disorders (300.0, 300.2, 300.3, 304, 308.3).
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was common before the first depot injection. The
mean oral antipsychotic MPR during the 180-day period
before starting depot medications was approximately 0.6
for all 3 groups, and most patients had oral antipsychotic
MPRs below 0.80 (table 2).
Depot Treatment Episode
Fewer than 1 in 10 depot patients continued on long-
acting injections for 180 days following the first injection
(table 3). The mean duration of depot treatment episodes
was significantly longer for HD patients than for FD
patients (table 3). The period from first to last injection
of the treatment episode was also significantly longer for
patients treated with HD than FD, while the mean depot
MPR over the first 90 days was significantly greater for
patients treated with HD than either FD or LAR. At the
same time, patients treated with LAR, which has the
shortest recommended dosing interval, received a signifi-
cantly larger number of injections during their depot
treatment episodes than patient treated with FD or
HD (table 3).
During depot treatment, a substantial proportion of
the patients also received antidepressant medications,
anxiolytics/hypnotics, and mood stabilizers (table 3) as
well as oral antipsychotic medications (table 4). The
oralantipsychoticmedicationwasfrequentlytheoralfor-
mulation of the depot medication.
After controlling for several background characteris-
tics, the overall median length of depot treatment or
STR was significantly greater for LAR and HD than FD
(table 5). In stratified analyses, the duration of LAR
treatment episodes was significantly greater than FD epi-
sodes for males, patients 45–64 years, and patients who
were other than white in race (table 5). Among patients
who were white in race, the STR was significantly greater
for HD than LAR (table 5).
Following Depot Treatment Episode
During the 45-day period following depot antipsychotic
discontinuation, more than three-quarters of each group
received oral antipsychotic medications. The oral anti-
psychotic medication was commonly the oral formula-
tion of the antipsychotic medication that patients
previously received as an injection (table 6). A signifi-
cantly larger proportion of post-LAR than post-FD
patients had oral antipsychotic MPRs <0.80 during
the period following long-acting injection treatment.
As compared with patients who discontinued HD,
thosewhodiscontinuedFDweresignificantlymorelikely
tobetreatedwithanantidepressantoranxiolytic/hypnotic
medication during the period following long-acting
Table 2. Pharmacological Treatment of Patients With Schizophrenia During the 180-d Period Before Starting FD, HD, or LAR
Treatment
FD Patients, %
(N = 948)
HD Patients, %
(N = 1631)
LAR Patients, %
(N = 116)
Statistics
Group
Differences
a v
2 df P
Any oral antipsychotic 92.9 91.1 96.6 6.1 2 .046 LAR > HD
Any oral atypical antipsychotic 84.6 85.5 95.7 10.4 2 .006 LAR > HD, FD
Selected oral antipsychotics
Fluphenazine 34.5 3.7 9.5 45.5 2 >.0001 FD > LAR > HD
Haloperidol 13.8 42.2 23.3 227.9 2 >.0001 HD > LAR > FD
Risperidone 32.8 38.9 70.7 63.8 2 >.0001 LAR > FD, HD
Aripiprazole 3.8 4.6 16.4 36.0 2 >.0001 LAR > FD, HD
Clozapine 10.4 10.6 10.3 0.1 2 .98
Olanzapine 45.2 41.8 36.1 4.9 2 .09
Quetiapine 32.2 31.7 32.8 0.1 2 .94
Ziprasidone 13.1 11.1 14.7 3.1 2 .22
2þ Oral antipsychotics 65.1 64.0 75.0 5.5 2 .07
Antipsychotic, MPR
b <0.80 53.5 58.5 61.2 6.9 2 .03 HD > FD
Antipsychotic gap >30 d 22.7 24.5 29.5 2.8 2 .24
Other psychotropic medications
Antidepressant 50.2 47.7 56.0 3.9 2 .14
Anxiolytic/hypnotic 47.2 45.4 56.9 6.1 2 .048 LAR > FD, HD
Mood stabilizer 56.3 56.1 60.3 0.8 2 .67
Fd f P
Antipsychotic MPR, mean (SD) 0.64 (0.32) 0.61 (0.32) 0.63 (0.29) 1.6 2, 2612 .19
Note: Data from 2001 to 2004 Medi-Cal. FD denotes fluphenazine decanoate, HD denotes haloperidol decanoate, and LAR denotes
long-acting risperidone. All analyses are based on 180-d period before the start of first depot injection.
aGroup differences, P < .05.
bMPR denotes medication possession ratio and is defined as the proportion of days of medication over the 180-d treatment period.
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were significantly more likely than LAR patients to be
subsequently treated with a mood stabilizer (table 5).
Discussion
Thecurrent findings suggestthat early discontinuationof
depot antipsychotic medication is quite common in the
community treatment of schizophrenia. After 180 days,
only 9.7% of HD patients, 5.4% of FD patients, and
2.6% of LAR patients were continuing to receive the
same long-acting antipsychotic medication. The longer
typical injection interval for HD (28 days) as compared
with FD (21 days) or LAR (14 days) appeared to contrib-
ute to the significantly higher proportion of HD patients
continuing depot treatment for at least 6 months. Al-
though patients starting HD or FD tended to receive
a similar number of injections during their treatment ep-
isode, the period from the first to last injection was sig-
nificantly longer for patients receiving HD than FD. In
analyses that controlled for several background patient
characteristics, treatment with HD or LAR was associ-
atedwith significantly longer episodes of depot treatment
thantreatmentwithFD.Thereasonsforthesedifferences
are unclear but may involve medication-related differen-
ces in drug tolerability, effectiveness, injection intervals,
or other factors.
The current findings reveal substantially lower rates of
continuity with depot antipsychotic treatment than has
been reported from patients in research studies. In one
prospective British study of 100 patients starting LAR,
51% discontinued during the first 6 months.
26 The
most common reasons for discontinuation were that
themedicationwasconsideredineffectivebytheprescrib-
ing physician (47%), refused by the patient (35%), or not
tolerated by the patient (18%).
26 In randomized con-
trolled trials with conventional long-acting antipsychotic
injections, discontinuation rates have ranged from as low
as 12.5% over 36 weeks
27 and 19% over 24 weeks
28 to
50.5% at 52 weeks.
29 Because randomized controlled tri-
als involve carefully selected subjects who consent to ex-
tendedassessments and care under controlled conditions,
significantly lower discontinuation rates are to be antic-
ipated than in usual practice conditions. In community
Table 3. Characteristics of Schizophrenia Patients During Treatment With FD, HD, or LAR
Characteristic
FD Patients, %
(N = 948)
HD Patients, %
(N = 1631)
LAR Patients, %
(N = 116)
Statistics
Group
Differences
a v
2 df P
Depot for  180 d 5.4 9.7 2.6 20.0 2 <.0001 HD > LAR, FD
Fd f P
Injection episode, d
[mean (SD)]
58.2 (53.6) 71.7 (56.2) 60.5 (48.8) 18.3 2, 2692 <.0001 HD > FD
First to last injection, d
[mean (SD)]
38.7 (54.5) 45.8 (58.7) 47.7 (49.2) 5.0 2, 2692 .007 HD > FD
Number of injections
[mean (SD)]
2.8 (2.4) 2.9 (2.4) 4.4 (2.9) 24.2 2, 2692 <.0001 LAR > FD, HD
First 90 d, depot MPR
b
[mean (SD)]
0.40 (.19) 0.49 (0.22) 0.40 (0.19) 62.6 2, 2692 <.0001 HD > LAR, FD
FD/LAR, OR
(95% CI)
c
HD/LAR, OR
(95% CI)
c
Other psychotropic medications (%)
Antidepressant 35.4 36.0 34.5 0.18 2 .91 1.1 (0.7–1.6) 1.0 (0.7–1.5)
Anxiolytic/hypnotic 35.1 36.6 36.2 0.57 2 .77 1.0 (0.6–1.4) 1.0 (0.6–1.4)
Mood stabilizer 46.6 50.2 31.0 17.1 2 .0002 2.0 (1.3–3.0) 2.1 (1.4–3.2)
Acute mental health care (%)
Emergency visit 10.1 8.2 3.4 7.1 2 .03 3.2 (1.1–8.9) 2.3 (.8–6.4)
Hospital admission 0.6 0.4 0 1.5 2 .47 N/A N/A
Note: Data from 2001 to 2004 Medi-Cal. FD denotes fluphenazine decanoate, HD denotes haloperidol decanoate, and LAR denotes
long-acting risperidone. All analyses are based on long-acting injection treatment episode.
aGroup differences, P < .05.
bMPR denotes medication possession ratio and is defined as the proportion of days of depot medication during the first 90 d after the
first injection.
cResults for categorical variables are presented as odds ratios (ORs) followed by 95% confidence intervals (CIs). These results are from
separate logistic regressions for each row controlling for treatment duration with antipsychotic agent as the dependent variable with
LAR as the reference group. Results for continuous variables are presented as significant pairwise comparisons for Tukey’s HSD (P < .05).
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choticinjections because of problems with adherence with
oral antipsychotic medications.
Inthecurrentstudypopulation,therewereseveralsim-
ilarities between schizophrenia patients who initiated
FD, HD, or LAR injections. A majority of patients start-
ing each of the preparations had oral antipsychotic
MPRs during the period before the first injection below
0.80, suggestive of nonadherence with oral antipsychotic
medications.
3 Previous research has linked medication
nonadherence to initiation of depot antipsychotic medi-
cations.
30 Clinical characteristics related to medication
nonadherence, including substance use disorders
23,24
and emergency mental health treatment,
31,32 were also
common among patients who started each of the depot
medications.
Inrelationtothegeneralpopulation,adultswithsevere
psychiatricdisordershaveelevatedratesofseveralmedical
disorders, including heart disease,
33,34 diabetes,
35,36 and
obesity.
37,38 Among patients with schizophrenia starting
Table 5. Mean and Median Depot Treatment Duration of Patients With Schizophrenia Starting Fluphenazine Decanoate (FD),
Haloperidol Decanoate (HD), and Long-Acting Risperidone (LAR)
Group
Mean, Days (SD) Median, Days STR
a (95% CI)
FD HD LAR FD HD LAR FD HD LAR
Injection
Total 58.2 (53.6) 71.7 (56.2) 60.5 (48.8) 21 28 49 0.81 (0.70–0.93) 1.09 (0.95–1.25) 1.00
Sex
Male 56.2 (57.8) 71.6 (55.9) 64.3 (50.2) 21 29 56 0.78 (0.63–0.95) 1.11 (0.91–1.36) 1.00
Female 61.3 (54.6) 71.7 (57.3) 56.8 (47.5) 21 28 46 0.86 (0.71–1.05) 1.06 (0.87–1.28) 1.00
Age
18–44 (y) 59.1 (53.8) 70.0 (55.4) 55.6 (43.7) 21 28 47 0.64 (0.73–1.04) 1.14 (0.96–1.36) 1.00
45–64 (y) 57.1 (53.5) 74.4 (58.1) 69.1 (56.1) 21 31 54 0.71 (0.56–0.90) .95 (0.79–1.25) 1.00
Race
White 59.4 (53.1) 73.5 (56.7) 58.3 (48.3) 21 35 45 0.81 (0.68–1.01) 1.24 (1.02–1.51) 1.00
Other 56.9 (53.9) 70.2 (56.1) 62.7 (49.5) 21 28 54 0.81 (0.67–0.99) 0.99 (0.81–1.20) 1.00
Note: Data are from the California Medicaid program, 2001–2004. CI, confidence interval.
aSTR denotes survival time ratio. It is a ratio of the adjusted median time to depot discontinuation between antipsychotic treatment
groups with LAR as the reference group. The STRs are adjusted for patient age, sex, race, use of inpatient and emergency mental health
services, outpatient mental health treatment, outpatient general medical treatment, and treatment with antidepressants, mood
stabilizers, anxiolytic/hypnotics, and oral antipsychotic medications.
Table4. OralAntipsychoticMedicationTreatmentofPatientsWithSchizophreniaDuringtheFirst90-dAfterStartingFD,HD,andLAR
Oral Medication FD Patients (%) HD Patients (%) LAR Patients (%)
Statistics
v
2 df P
Any oral antipsychotic
0–30 d (n1 = 419, n2 = 794, n3 = 75) 92.8 91.1 89.3 1.6 2 .44
31–60 d (n1 = 321, n2 = 669, n3 = 49) 91.6 86.6 77.6 10.0 2 .007
61–90 d (n1 = 212, n2 = 509, n3 = 27) 92.0 85.7 70.4 12.0 2 .002
Second generation antipsychotic
0–30 d (n1 = 419, n2 = 794, n3 = 75) 83.3 81.2 82.7 0.8 2 .67
31–60 d (n1 = 321, n2 = 669, n3 = 49) 84.1 75.9 69.4 10.8 2 .004
61–90 d (n1 = 212, n2 = 509, n3 = 27) 84.4 74.1 66.7 10.6 2 .005
Oral form of depot antipsychotic
0–30 d (n1 = 419, n2 = 794, n3 = 75) 42.5 44.7 64.0 12.0 2 .002
31–60 d (n1 = 321, n2 = 669, n3 = 49) 33.0 35.7 46.9 3.7 2 .16
61–90 d (n1 = 212, n2 = 509, n3 = 27) 32.6 33.8 48.2 2.6 2 .27
Note: Data from 2001 to 2004 Medi-Cal. FD denotes fluphenazine decanoate, HD denotes haloperidol decanoate, and LAR denotes
long-acting risperidone. All analyses are based on long-acting injection treatment episode. Results are percentages of patients within
each category prescribed any oral antipsychotic, second generation antipsychotic, or oral form of the depot antipsychotic during the 3
time periods. The number of patients in the denominators are represented as n1 = FD patients, n2 = HD patients, and n3 = LAR
patients.
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differences in the proportion who had recently re-
ceived treatment for diabetes, obesity, or hyperlipidemia.
However, prior to depot initiation, patients who started
FD made significantly more general medical visits than
those who started the other 2 antipsychotic medications.
The reasons for this difference are not clear.
The 3 patient groups received broadly similar adjunc-
tive psychopharmacological treatments during the 180
days before their first antipsychotic injection. After start-
ing depot injections, most patients received oral antipsy-
choticmedicationsandmanyreceivedmorethanoneoral
antipsychotic medication. Prescriptions of other psycho-
tropic medications, especially mood stabilizers and anti-
depressants, were also common. In one large European
observational study of outpatients with schizophrenia,
a substantial proportion of patients received anxiolytic/
hypnotics (29.8%) at the time of starting conventional
long-acting injection antipsychotics, but relatively few
received antidepressants (9.5%) or mood stabilizers
(6.8%).
39 Although such point estimates would be
expected to be lower than cumulative estimates over
180 days as presented in the current study, it is nonethe-
less striking that such a great disparity exists between the
high rates of anxiolytic/hypnotic, antidepressant, and
mood stabilizer coprescription in the California sample
and the low rates in the European sample. As compared
with schizophrenia patients in Europe, proportionately
fewer patients in the California Medicaid program are
treated with long-acting antipsychotic medications. It
is possible that higher levels of psychiatric comorbidity
within the California sample contribute to their higher
rates of psychotropic coprescription.
A recent literature review found no convincing evi-
dence to support or disprove the efficacy of antidepres-
sant treatment for depressive symptoms in adults with
schizophrenia.
40 Evidence for an augmenting effect of
mood stabilizers in the antipsychotic treatment of schizo-
phrenia is similarly mixed.
41,42 Given that concurrent
medication administration increases the risk of adverse
drug reactions,
43 efforts to reduce psychotropic copre-
scription might help improve tolerability and adherence
of antipsychotic medications.
44
Treatment with mood stabilizers was significantly less
common among patients during treatment with LAR
than during treatment with FD or HD. It is possible that
this difference reflects inherent mood stabilizing proper-
ties of risperidone
45,46 or less mood instability in patients
selected for LAR therapy.
Following discontinuation of long-acting antipsychotic
medications,mostpatientscontinuetoreceiveoralantipsy-
chotic medications. This suggests that problems with
Table 6. Mental Health Treatment of Patients With Schizophrenia During the 45 Days After Discontinuing FD, HD, or LAR
Medication
FD Patients, %
(N = 816)
HD Patients, %
(N = 1301)
LAR Patients, %
(N = 102)
Statistics
Group
Differences
a v
2 df P
Any oral antipsychotic 77.4 78.9 75.5 1.1 2 .57
Oral antipsychotic medications
Fluphenazine 24.0 1.7 4.9 279.7 2 <.0001 FD > LAR > HD
Haloperidol 6.0 23.5 7.8 118.1 2 <.0001 HD > FD, LAR
Risperidone 20.1 21.6 43.4 28.4 2 <.0001 LAR>FD, HD
Olanzapine 30.0 30.0 23.5 1.9 2 .39
Quetiapine 21.4 19.1 13.7 4.2 2 .12
Ziprasidone 6.5 6.1 4.9 0.4 2 .80
Aripiprazole 2.0 3.1 5.9 6.0 2 .049 LAR > FD
Clozapine 7.8 7.6 5.9 0.5 2 .78
Other psychotropic medications
Antidepressant 38.2 33.9 39.2 4.7 2 .10 FD > HD
Anxiolytic/hypnotic 34.9 29.8 36.3 7.1 2 .03 FD > HD
Mood stabilizer 46.6 45.5 35.3 2.7 2 .26 FD, HD > LAR
Antipsychotic gap of >30 days
among oral users
5.5 6.6 9.1 1.8 2 .41
Antipsychotic MPR
b <0.80 35.9 38.7 48.0 6.2 2 .046 LAR > FD
Acute mental health care (%)
Emergency visit 8.1 6.2 6.9 2.9 2 .23
Hospital admission 0.6 0.6 0 0.6 2 .73
Note: Data from 2001 to 2004 Medi-Cal. FD denotes fluphenazine decanoate, HD denotes haloperidol decanoate, and LAR denotes
long-acting risperidone.
aGroup differences, P < .05.
bMPR denotes medication possession ratio and is defined as the proportion of days of any antipsychotic medication treatment during
the 45 days after depot injection treatment.
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essarilygeneralizetopatientrejectionoforalantipsychotic
medications. A longer period of follow-up after discontin-
uationoflong-actingantipsychoticmedicationswouldper-
mitamorecompleteassessmentofthefrequencywithwhich
these patients are restarted on long-acting medications.
Thisstudyhasseverallimitations.First,althoughphar-
macyclaimsmeasureoralpsychotropicmedicationutiliza-
tion with reasonable accuracy,
47,48 oral prescription fills
areonlyaproxyforactualmedicationuse.Second,because
patientswhoreceiveLARlikelydifferfromthoseselected
for the older depot medications, group comparisons are
vulnerable to selection biases. Medicaid data provide no
information concerning several factors such as clinical ef-
ficacy, medication tolerability, adverse effects, patient
medicationpreferences,illnessinsight,andfamilysupport
that may influence antipsychotic selection. Without ran-
domassignment,itispossiblethatgroupdifferencesinout-
comeareaconsequenceofpretreatmentgroupdifferences
ratherthanthetreatmentsthemselves.Third,LARwasap-
proved by the Food and Drug Administration during the
studyperiod.Asaresult,ourdataprovideinformationon
LARearlyinitsmarketcycle.Overtime,asreimbursement
factors change and clinicians gain greater training in ad-
ministration of LAR microspheres, patient selection for
LAR may change. Similar channeling biases have been
demonstratedinselectionofantipsychoticmedications.
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Fourth,inordertohelpensurecompleteprescriptiondata
retrieval, patients with extensive inpatient treatment be-
forestartingdepotwereexcluded.Thisexclusionmaylimit
the generalizability of the findings. Fifth, the results may
underestimatethedurationoftreatmentepisodesthatwere
initiatedduringaninpatientstay.Sixth,theposttreatment
follow-upinvolvedasmallnumberofpatientsoverashort
timeperiod.Finally,theresultsmaynotextendtopatients
who are not covered by the Medicaid program.
Patients with schizophrenia who initiate long-acting an-
tipsychoticinjectionscommonlyexhibitevidenceofnonad-
herence with oral antipsychotic medications in the months
before their first injection. Patients starting HD, FD, and
LARalsocommonlyreceiveprescriptionsforotherclasses
of psychotropic medications. Treatment with long-acting
antipsychotic medications is often brief, usually lasting
no longer than 7–10 weeks. Detailed clinical research is
neededtodeterminetheroleofmedication-relatedfactors,
suchasdosing,tolerability,andefficacy,aswellasotherkey
clinicalandpsychosocialfactorsthatcontributetotheearly
discontinuation of depot antipsychotic medications. More
importantly, research is needed to develop intervention
strategiesthatwillenhancethecontinuityofdepotantipsy-
chotic therapy in community treatment.
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